Creative Biolabs has developed an original CBpHLA™ cancer target and TCR analysis platform to support the innovative TCR-T treatment program. We believe, with our team of experts and most up-to-date facilities, we could help you to tailor the best TCRs to suit the best to your cancer immunotherapy projects.
When a large number of somatic mutations occur in major histocompatibility complex class I (MHCI) molecules in human tumors, it is necessary to screen them to reduce potential immunogenicity. Therefore, we have established a novel CBpHLA™ technology platform based on whole exome/transcriptome sequencing analysis combined with mass spectrometry to detect the ability of mutant peptides to recognize tumor exons and construct antigen libraries.
In addition to detecting genomic mutations, our CBpHLA™ technique can also be used for RNA editing peptide analysis. Up to now, we have provided a full range of services on the mechanism of the natural presentation of RNA editing peptides in human leukocyte antigen (HLA) molecules.
Creative Biolabs has developed a proprietary CBpHLA™ cancer target identification and TCR engineering platform. We are committed to continuously pioneering new areas of TCR therapy, helping our customers identify perfect, safe, and effective cancer targets, and advancing their clinical application in TCR therapy. Currently, based on our unique targeting and TCR therapy development technology, we can identify and design candidate T cell receptors with high affinity and specificity.
Fig. 1 The Routine Analysis Process of CBpHLA™ Platform.
Creative Biolabs is committed to developing and commercializing the next generation of TCR-based immunotherapies for a variety of blood and solid tumor treatments. Using our unique CBpHLA™ technology, we can select precise targets that are specifically expressed in tumors and screen for TCRs with high affinity for tumors to develop more precise and safer therapies.
Fig. 2 The Advantages of the CBpHLA™ Platform.
More recently, we have used the CBpHLA™ technique to fully and accurately characterize HLA peptide sets in healthy tissues and disease states, respectively. We used a combination of computer simulation and experimental methods to successfully distinguish true HLA ligands from isolated HLA-independent proteolytic fragments. Furthermore, we have established standards for data inclusion and parameter setting to ensure the system suitability of the chromatographic system. In addition, we are continuously developing high-throughput sequence validation through the synthesis of isotope-labeled internal standard fragmentation models.
Creative Biolabs has developed a fail-proof CBpHLA™ analysis platform for our clients all over the world. We have integrated high-quality TCR therapy solutions that are based in America and span the entire development chain from discovery to commercialization. Our company offers the best guarantee in a series of target identification and TCR discovery for various types of cancer therapy. If you are interested in our services, please feel free to contact us for closer communication to learn how we can be involved in your project. Separate services or integrated end-to-end solutions are all welcomed.
For Research Use Only | Not For Clinical Use
Download our brochure